Volovăţ C, Volovăţ Simona Ruxandra, Dogaru C, Vulpoi Carmen
Universităţii de Medicină si Farmacie "Gr.T. Popa" Iaşi.
Rev Med Chir Soc Med Nat Iasi. 2011 Jan-Mar;115(1):53-7.
To evaluate and compare the impact on quality of life of tamoxifen and aromatase inhibitors (AIN's) in adjuvant settings, at women with breast cancer.
From a total of 441 patients with breast cancer with hormonal treatment, were selected 177 of patients with adjuvant hormonal treatment (95 with tamoxifen treatment and 82 with AIN's treatment). These patients have completed the EORTC QLQ C-30 and EORTC QLQ BR23 questionnaires after 1 month of treatment (baseline), at 2 year of treatment with tamoxifen versus aromatase inhibitors (exemestane, anastrazole, letrozole). Mean change score from baseline and 2 years of treatment were compared in the both arms (tamoxifen vs. AIN's).
In both arms, after two years, a decreased QOL was observed as compared with the baseline. In the tamoxifen arm, global health status (GHS) and breast symptoms score (BRBS) were similar comparative with AIN's arm at baseline, with a similar status at 2 years measurement.
The global health status (GHS) and breast symptoms score (BRBS) shows that there is no difference in the QOL at the women with breast cancer treated with tamoxifen, comparative with the women treated with AIN's. We conclude that AIN's did not have an adverse impact on overall QOL, comparative with tamoxifen, in adjuvant settings.
评估并比较他莫昔芬和芳香化酶抑制剂（AIs）在辅助治疗环境中对乳腺癌女性患者生活质量的影响。
在总共441例接受激素治疗的乳腺癌患者中，选取177例接受辅助激素治疗的患者（95例接受他莫昔芬治疗，82例接受AIs治疗）。这些患者在治疗1个月后（基线）、接受他莫昔芬或芳香化酶抑制剂（依西美坦、阿那曲唑、来曲唑）治疗2年后完成了欧洲癌症研究与治疗组织（EORTC）QLQ C - 30和EORTC QLQ BR23问卷。比较了两组（他莫昔芬组与AIs组）从基线到治疗2年的平均变化得分。
两组在两年后与基线相比生活质量均有所下降。在他莫昔芬组中，基线时总体健康状况（GHS）和乳腺症状评分（BRBS）与AIs组相似，在2年测量时状况也相似。
总体健康状况（GHS）和乳腺症状评分（BRBS）表明，接受他莫昔芬治疗的乳腺癌女性与接受AIs治疗的女性在生活质量方面没有差异。我们得出结论，在辅助治疗环境中，与他莫昔芬相比，AIs对总体生活质量没有不利影响。
